aurobindo pharma has announced the retirement of Mr. N. Ravi Kiran, Chief Business Officer, Emerging Markets, from the company. The retirement will be effective from the close of business hours on April 30, 2026. This disclosure was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company submitted the information to both the National Stock Exchange of India Limited and BSE Limited as part of its compliance with the SEBI Listing Regulations. The announcement was digitally signed by B Adi Reddy, Company Secretary, on April 30, 2026.

Details of the Management Change

The company provided specific details regarding the management change in an annexure to the disclosure. The key particulars are outlined below:

The retirement pertains specifically to Mr. N. Ravi Kiran's role as Chief Business Officer, Emerging Markets, which is classified as a senior management position within the organization. The company has confirmed that all required disclosures under Regulation 30 have been provided to the stock exchanges.

Aurobindo Pharma Limited, headquartered in Hyderabad, Telangana, operates with its corporate office at Galaxy, Hyderabad Knowledge City, and registered office at Maithrivihar, Ameerpet. The company can be contacted through its official website at www.aurobindo.com or via email at info@aurobindo.com .

Aurobindo Pharma has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per ml. The approved product is bioequivalent and therapeutically equivalent to the reference listed drug Ravicti Oral Liquid of Horizon Therapeutics U.S. Holding LLC.

Market Opportunity and Product Details

The newly approved Glycerol Phenylbutyrate Oral Liquid represents a significant commercial opportunity in the US pharmaceutical market. The product targets a substantial market segment with specific therapeutic applications.

Therapeutic Application and Manufacturing

Glycerol Phenylbutyrate Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and amino acid supplementation alone. This specialized therapeutic application addresses a critical medical need in the treatment of rare metabolic disorders.

The company will manufacture the approved product at its Unit-III facility and plans an immediate launch in the US market. This rapid market entry strategy demonstrates Aurobindo Pharma's manufacturing readiness and regulatory compliance capabilities.

Regulatory Portfolio Expansion

With this latest approval, Aurobindo Pharma now holds a total of 579 ANDA approvals from the USFDA, comprising 556 final approvals and 23 tentative approvals. This milestone reinforces the company's strong regulatory track record and ability to navigate complex approval processes.

Strategic Significance

This USFDA approval strengthens Aurobindo Pharma's presence in the US pharmaceutical market and expands its product portfolio in specialized therapeutic areas. The approval demonstrates the company's continued focus on developing niche pharmaceutical products that address specific medical conditions and represent meaningful commercial opportunities in the global healthcare market.